# IMCIVREE® Knowledge Base

## Product Overview

**Generic Name:** Setmelanotide

**Brand Name:** IMCIVREE®

**Manufacturer:** Rhythm Pharmaceuticals, Inc.

**Mechanism:** MC4R Pathway agonist

---

## Indication (HCP Version)

IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to **Bardet-Biedl syndrome (BBS)**.

---

## Limitations of Use

IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective:
- Other types of obesity not related to BBS or other FDA-approved indications for IMCIVREE
- Obesity associated with other genetic syndromes
- General (polygenic) obesity

---

## What is Bardet-Biedl Syndrome?

**Bardet-Biedl syndrome (BBS)** is a rare genetic disease characterized by:
- Obesity (often with insatiable hunger/hyperphagia)
- Vision problems
- Extra fingers or toes
- Kidney abnormalities
- Learning difficulties
- Other multi-system complications

---

## MC4R Pathway

The **melanocortin-4 receptor (MC4R) pathway** is:
- A key neurosignaling pathway in the hypothalamus
- Responsible for regulating energy balance
- Central to understanding genetic obesity
- The target mechanism for IMCIVREE

---

## Important Safety Information (HCP)

### Contraindications
- Prior serious hypersensitivity to setmelanotide or any excipients in IMCIVREE
- Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported

### Warnings and Precautions

**Disturbance in Sexual Arousal:**
- Spontaneous penile erections in males
- Sexual adverse reactions in females
- Instruct patients with erections lasting >4 hours to seek emergency care

**Depression and Suicidal Ideation:**
- Depression, suicidal ideation, and depressed mood have occurred
- Monitor for new onset or worsening depression
- Monitor for suicidal thoughts or behaviors
- Consider discontinuing if suicidal thoughts/behaviors occur or persistent depression symptoms develop

**Hypersensitivity Reactions:**
- Serious hypersensitivity reactions (e.g., anaphylaxis) reported
- Advise patients to promptly seek medical attention if suspected
- Discontinue IMCIVREE

**Skin Hyperpigmentation and Changes:**
- Darkening of pre-existing nevi (moles)
- Development of new melanocytic nevi
- Perform full body skin examination prior to initiation
- Monitor periodically during treatment

**Benzyl Alcohol Preservative Risk:**
- IMCIVREE not approved for use in neonates or infants
- Serious and fatal adverse reactions including "gasping syndrome" can occur
- Risk in neonates and low birth weight infants

### Adverse Reactions

**Most Common (incidence ≥20%):**
- Skin hyperpigmentation
- Injection site reactions
- Nausea
- Headache
- Diarrhea
- Abdominal pain
- Vomiting
- Depression
- Spontaneous penile erection

### Use in Specific Populations

**Pregnancy:**
- Discontinue IMCIVREE when pregnancy is recognized
- Unless benefits outweigh potential risks to fetus

**Breastfeeding:**
- Treatment with IMCIVREE is not recommended when breastfeeding

---

## Important Safety Information (Patient Version)

### What is IMCIVREE?

IMCIVREE is a prescription medicine used in adults and children 2 years of age and older with obesity due to Bardet-Biedl syndrome (BBS) to help them lose weight and keep the weight off.

### Who Should NOT Use IMCIVREE?

IMCIVREE is not for use in people with:
- Other types of obesity not related to BBS
- Other FDA-approved uses of IMCIVREE
- Obesity associated with other genetic conditions
- General obesity

It is not known if IMCIVREE is safe and effective in children under 2 years of age.

### Do Not Use If:

You have had a serious allergic reaction to IMCIVREE or any of its ingredients. Serious allergic reactions, including anaphylaxis, can happen.

### Before Using, Tell Your Healthcare Provider If You:

- Have or have had areas of darkened skin
- Have or have had depression or suicidal thoughts
- Have kidney problems
- Are pregnant or planning to become pregnant
- Are breastfeeding or plan to breastfeed

### Tell Your Healthcare Provider About:

All medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

### Instructions for Use

See the Instructions for Use that come with IMCIVREE for:
- Preparation
- Injection
- Safe syringe disposal instructions

### Serious Side Effects

IMCIVREE may cause serious side effects, including:
- Sexual function problems in males and females
- Depression and suicidal thoughts or actions
- Serious allergic reactions
- Increased skin pigmentation and changes in moles
- Benzyl alcohol toxicity in premature or low-birth-weight infants

### Common Side Effects

Common side effects include:
- Darkened skin
- Injection site reactions
- Nausea
- Headache
- Diarrhea
- Stomach pain
- Vomiting
- Depression
- Spontaneous erections in males

These are not all the possible side effects.

### Reporting

Call your doctor for medical advice.

Report negative side effects to:
- FDA: 1-800-FDA-1088 or www.fda.gov/medwatch
- Rhythm Pharmaceuticals: 833-789-6337

---

## Brand Information

### Visual Identity

**Primary Colors:**
- Teal Header: #1c7b80
- Teal Primary: #007a80
- Light Background: #f6fbfb
- ISI Background: #fafafa
- Text Gray: #4a4f55

**Design Elements:**
- Rounded shapes
- Soft shadows
- Calm, supportive visuals
- Patient-focused (never weight-stigmatizing)
- Clean typography
- Sans-serif fonts (Arial/Helvetica)

### Logo
- IMCIVREE logo: https://rhythmtx.com/wp-content/uploads/2024/10/imcivree-logo-big.png

### Approved Images

**MOA (Mechanism of Action):**
- https://www.imcivree.com/static/hcp-bbs-functional-mc4r-3e490b24a8f4f9bcc4ede22918fb38da.png

**Summary/Dosing Box:**
- https://www.imcivree.com/static/dosing-box-953935ca5e56951d5e90c73760348f8e.png

**Dosing Chart (Young Children):**
- https://www.imcivree.com/static/hcp-bbs-dosing-chart-young-children-0287c959c1242bd92cc8832f0b0f0c42.png

**Icons:**
- Decision: https://www.imcivree.com/static/deciding-7d8ad39aafa2238baac466e8d01b8e67.svg
- Learning: https://www.imcivree.com/static/learning-16a302a10874bd1676177c6ebe63cf9a.svg

### Social Media Guidance

**Approved Hashtags:**
- #IMCIVREE
- #BardetBiedlSyndrome
- #BBSCommunity
- #RareDisease
- #PrescriptionMedication
- #PatientSupport
- #HealthyTogether
- #GeneticObesity
- #PatientEducation
- #KnowYourOptions

**Who to Tag:**
- @rhythmpharma
- Patient advocacy groups (BBS-specific)
- Rare disease organizations
- Genetic obesity support organizations
- NEVER tag individual patients

**Visual Guidelines for Social:**
- Teal-forward calm visuals
- Rounded shapes, soft shadows
- Neutral, patient-supportive tone
- NO weight imagery
- NO before/after comparisons
- NO medical procedure visuals
- Clean typography
- Preferred dimensions: 1080×1350 (portrait) for Instagram

### Messaging Tone

**What to DO:**
- Use calm, supportive, educational tone
- Focus on patient empowerment
- Emphasize genetic nature of condition
- Provide clear, factual information
- Use person-first language
- Be compassionate and non-judgmental

**What to AVOID:**
- Weight-loss transformation language
- Weight-stigmatizing imagery or words
- Comparisons with other treatments
- Fear-based messaging
- Unapproved claims or benefits
- Medical jargon without explanation

---

## Legal & Compliance

### Copyright
© 2025, Rhythm Pharmaceuticals, Inc. All rights reserved.

### Trademarks
Rhythm, IMCIVREE, and their logos are trademarks of Rhythm Pharmaceuticals, Inc.

### Adverse Event Reporting
- Rhythm Pharmaceuticals: 833-789-6337
- FDA: 1-800-FDA-1088
- FDA MedWatch: www.fda.gov/medwatch

### Prescribing Information
Full Prescribing Information available at official IMCIVREE website

---

## Patient Support Program

**Rhythm InTune:**
- Resources for patients and caregivers
- Education and information
- Support for individuals living with rare MC4R pathway diseases
- Focused on Bardet-Biedl syndrome

---

## HCP Resources

**Website:** https://hcp.rhythmtx.com/

**Educational Focus:**
- Understanding rare neuroendocrine diseases
- Diagnostic guidance
- Treatment options
- MC4R pathway education
- Clinical evidence and publications

---

## Related Educational Platforms

**DifferentObesity.com:**
- Educational platform about obesity classification
- Symptom recognition
- Understanding genetic vs. general obesity

---

## Company Information

**Rhythm Pharmaceuticals, Inc.**
- 222 Berkeley Street, 12th Floor
- Boston, MA
- United States

**Mission:**
"Transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause."

**Focus Areas:**
- Rare neuroendocrine diseases
- Hyperphagia (insatiable hunger)
- Genetic obesity
- MC4R pathway disorders

---

## Content Creation Guidelines

### When Creating IMCIVREE Content:

**Always Include:**
- Full ISI (Important Safety Information)
- AMA-style references for all claims
- Proper superscripts for citations
- Compliant, FDA-approved language only

**Never Include:**
- Off-label uses
- Unsubstantiated claims
- Comparisons to competitors
- Weight-stigmatizing language
- Invented data or statistics
- Modified or paraphrased ISI

**Reading Level:**
- Patient content: 6th-8th grade
- HCP content: Professional but concise

**Segment Considerations:**
- HCP segments: Loyalist, Champion, Non-loyalist, etc.
- Patient segments: Newly diagnosed, treatment-experienced, caregivers

---

## Notes for Content Creators

1. All product mentions require context (indication, population)
2. Subject lines should NEVER include product name
3. Email preheaders should complement subject without repetition
4. Social posts for patients require full ISI block
5. References must be verifiable and AMA-formatted
6. Visual content must align with brand color palette
7. All claims must be on-label and referenced
8. MLR approval required before publication
9. Content cannot be modified post-MLR without re-approval
10. Patient privacy and dignity must be respected in all content
